Mitochondrial DNA Mutations Accumulate Clonally but Cannot Be Repaired In Vivo

Mitochondria accumulate DNA mutations at 10-17x the rate of nuclear DNA due to poor repair mechanisms. Damaged mitochondria can outcompete healthy ones within a cell through 'clonal expansion.' There is no approved therapy to selectively remove or repair mutant mtDNA, leaving cells increasingly energy-starved with age.

Each cell contains 100-10,000 mitochondria with a 16.5 kb circular genome (mtDNA). Mitophagy declines with age. MitoTALENs and mito-ZFNs can cut mutant mtDNA specifically, but delivery to all affected cells in vivo is unsolved. DdCBEs (DddA-derived cytosine base editors) can edit mtDNA but face the double-membrane delivery barrier. Urolithin A enhances mitophagy but clinical benefits in humans are modest.

Why It Matters

Mitochondrial dysfunction is one of the nine Hallmarks of Aging. Primary mitochondrial diseases affect ~1 in 5,000, but age-related decline affects everyone over 60. Linked to sarcopenia (10-16% of elderly, $18.5B/year US healthcare cost), heart failure, Parkinson's, and age-related hearing loss.

Startup Approach

Build mitochondrial genome editing platform using next-gen DdCBEs with enhanced import. Package in AAV9 or LNPs with tissue-specific promoters. Start with monogenic mitochondrial disease (MELAS or LHON), then expand to age-related heteroplasmy reduction.

NIH Funding

NIA Geroscience portfolio includes mitochondrial dysfunction as core pillar. NIH Reporter: ~$300M+ in active grants mentioning mitochondria and aging/disease.

Who's Working On It

Michal Minczuk (MRC Cambridge, mitoTALENs), Amazentis (urolithin A/Mitopure), Pretzel Therapeutics (mitochondrial gene therapy), Johan Auwerx (EPFL), Prime Medicine/Beam (exploring mtDNA base editing)